The National Institute for Health and Clinical Excellence (NICE) in Britain has recommended the use of AstraZeneca's new heart drug, Brilique as a cost effective medicine to treat heart patients in the country.
The recommendation will come as a big boost to AstraZeneca who is hoping to get the drug approved by the US Food and Drug Administration later next month. NICE said that Brilique can be seen as a viable treatment for people who suffer from a number of heart problems including heart attacks.
NICE said that the drug was better than Plavix and added that it reduced the number of fatal heart attacks by 21 percent.
However, a recent trial conducted for North American patients had found that Brilique fared worse than Plavix and its approval by the FDA, which the agency will decide on July 20, is not yet certain.